February 23, 2024


Eli Lilly CEO David Ricks on Q1 earnings: This year will be a year of growth and investment

Eli LillyFirst-quarter earnings missed expectations on Thursday, but the drugmaker raised its full-year guidance.

Ahead of the earnings release, the company also reported positive data for its weight-loss drug tezeparatide.

Related investment news

Higher guidance from Eli Lilly, Mounjaro figures lay solid ground for club names in 2023

CNBC Investment Club

Eli Lilly shares closed up nearly 4 percent at $390.35 apiece.

The company’s revenue fell 11% from a year earlier, as sales of its Covid-19 antibodies fell by $1.5 billion. Lilly reported revenue of $6.96 billion for the quarter, slightly above analysts’ expectations, but sales were down from $7.81 billion a year earlier.

The company reported adjusted earnings of $1.62 per share, below analysts’ expectations for $1.73 per share for the quarter.

Here’s how the company fared compared to analyst estimates compiled by Refinitiv:

  • Adjusted earnings: $1.62 per share vs. $1.73 per share expected
  • Revenue: $6.96 billion vs. $6.86 billion expected

The company’s net income for the quarter was $1.3 billion, or $1.49 per share, down 29% compared to the first quarter of 2022.

Eli Lilly raised its guidance for the year, largely due to a weaker dollar against major currencies. The company said it expected revenue between $31.2 billion and $31.7 billion, compared with a previous forecast of $30.3 billion to $30.8 billion.

The company raised its full-year adjusted earnings guidance to $8.55 a share from $8.35 to $8.65 to $8.85 a share.

Eli Lilly also released data on its weight-loss drug tirzepatide on Thursday morning ahead of the earnings report. Depending on the dose taken, patients who were overweight and with type 2 diabetes lost an average of 30 pounds to 34 pounds, compared with 7 pounds in the placebo group.

Lilly plans to finalize its application for Food and Drug Administration approval in the coming weeks.

CNBC Health and Science

Read CNBC’s latest global health coverage:

The FDA approved tirzepatide under the brand name Mounjaro in May 2022 for the treatment of adults with type 2 diabetes. Lilly’s first-quarter Mounjaro sales were about $567 million.

Lilly saw year-over-year revenue growth for several of Lilly’s key products. Sales of Lilly’s weekly injection of type 2 diabetes drug Trulicity hit $1.98 billion in the quarter, up 14% from $1.74 billion a year earlier.

Revenue from Lilly’s breast cancer drug Verzenio jumped 60% to $751 million, compared with $469 million in the first quarter of 2022.

Sales of Jardiance, a pill that lowers blood sugar in people with type 2 diabetes, jumped 38% to $578 million from $419 million a year earlier.

Correction: Lilly’s Mounjaro had sales of about $567 million in the first quarter. An earlier version incorrectly stated this figure.